Back to News
Market Impact: 0.25
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
Lexicon Pharmaceuticals reported a quarterly loss of $0.03 per share, narrower than the Zacks consensus estimate of a $0.06 loss. The loss compares with $0.04 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
LXRX0.35
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
- e.l.f. CEO: All of Our Brands Are Growing
- Behind Wall Street’s plunge: AI liquidation threatens Anthropic’s mega-IPO
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Automate Equity Research Workflows: A Control-First Guide
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience